Most patients who suffer from a chronic condition have multiple co-morbidities, making it difficult to manage the benefits and risks of multiple recommended treatments.
Phase III randomized controlled trials (RCTs) are viewed as the gold standard for comparing the efficacy and safety of a new drug with an existing drug. RCTs assess whether a drug works under strict conditions in a carefully selected patient population and using a set protocol.
Symptomatic coronary artery disease (CAD) affects over 150 million patients worldwide and is caused when atherosclerotic plaques form in the coronary arteries, limiting blood flow to the heart. The rupture of one of these plaques can lead to the formation of a blood clot, which partially or completely blocks blood flow, leading to an acute myocardial infarction (MI).
Thrombosis Connection, A Healthcare Professionals’ Forum
welcomes individuals interested in sharing, developing and
fostering innovative solutions in the field of thrombosis.